Biotech entity

Core Molding Technologies

Company CMT

All 1 tracked stories fall under one category: pharma. Core Molding Technologies is most often covered alongside Carvykti, which appears in 1 of these 1 story. Each carries 2 original sources on average. We currently track 1 Biotech story that mention Core Molding Technologies, all published on March 10, 2026.

Last mentioned: Mar 10, 2026

Entity pulse

Recent coverage · Core Molding Technologies

1 story
5 avg impact
0% positive
0% negative
  • 100% neutral

Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.

What the coverage shows about Core Molding Technologies

All 1 tracked stories fall under one category: pharma. Core Molding Technologies is most often covered alongside Carvykti, which appears in 1 of these 1 story. Each carries 2 original sources on average. We currently track 1 Biotech story that mention Core Molding Technologies, all published on March 10, 2026.

Stories tracked
1
Sources per story
2

Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 19 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.

Coverage cohort

Appears alongside

Other entities that clear the same relevance threshold in stories also covering Core Molding Technologies. Shared-story counts are live from our verified record — not editorial picks.

Timeline

  1. Pipeline Update

    Initial Phase 1 data released for LB2102 in solid tumors at a major medical conference.

  2. Manufacturing Expansion

    Obelisc facility in Belgium reaches full operational status for clinical and commercial supply.

  3. FY 2025 Earnings

    Legend Biotech reports full-year results and commercial highlights.

Stories mentioning Core Molding Technologies 1

Pharma Neutral

Legend Biotech Reports Robust 2025 Growth Driven by Carvykti Scaling

Legend Biotech (LEGN) has announced its fourth-quarter and full-year 2025 financial results, showcasing a significant surge in net trade sales for its CAR-T therapy, Carvykti. The company continues to expand its manufacturing footprint and advance its pipeline in solid tumors, solidifying its position as a leader in the cell therapy market.

2 sources

Core Molding Technologies is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.

See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.